Martin Hoffman, DO
Gastroenterology · Hartford, CTNPI 1922035617
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $197,453 of the $316,551 with a category attached, or 62.4%. 35 manufacturers reported payments, led by Gilead at 43.1% of the total. 2025 is the largest year on record at $108,237, 2.5 times the $43,235 reported in 2019. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 715 payments — averaging $442.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$136K
- Capsovision, Inc.$89K
- AbbVie$44K
- Madrigal Pharmaceuticals$41K
- Intercept Pharmaceuticals, Inc.$1K
- Bristol Myers Squibb$816
- plus $4K from 29 others
What the payments were for
- Consulting fees$94,32330%
- Speaking & faculty fees$197,45362%
- Travel & lodging$8,1823%
- Food & beverage$16,3405%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 276 | $136,436 |
| Capsovision, Inc. | 23 | $89,300 |
| AbbVie | 161 | $43,716 |
| Madrigal Pharmaceuticals | 35 | $41,418 |
| Intercept Pharmaceuticals, Inc. | 11 | $1,160 |
| Bristol Myers Squibb | 39 | $816 |
| Johnson & Johnson | 34 | $641 |
| Mallinckrodt Hospital Products Inc. | 16 | $488 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $482 |
| Pfizer | 17 | $279 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $246 |
| Ipsen Biopharmaceuticals, Inc | 5 | $215 |
| Regeneron Healthcare Solutions, Inc. | 4 | $168 |
| Ferring Pharmaceuticals Inc. | 6 | $115 |
| Bayer | 4 | $94 |
| Lilly USA, LLC | 4 | $93 |
| Eisai Inc. | 1 | $92 |
| Ardelyx, Inc. | 4 | $78 |
| Sanofi | 4 | $73 |
| Celltrion USA Inc. | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 2 | $69 |
| Medtronic | 2 | $58 |
| Fujifilm Healthcare Americas Corporation | 2 | $57 |
| Mirum Pharmaceuticals, Inc. | 2 | $56 |
| Shionogi Inc | 4 | $53 |
| Redhill Biopharma Inc. | 3 | $50 |
| AstraZeneca | 2 | $46 |
| Orphalan Inc | 2 | $44 |
| Merck | 2 | $26 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| UCB, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Boston Scientific | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CapsoCam Plus$71,600
- Epclusa$67,116
- REZDIFFRA$40,070
- Mavyret$39,653
- Vemlidy$20,817
- Livdelzi$18,440
- CapsoCam Colon$17,700
- OCALIVA$1,000
- ZEPOSIA$127
How this compares
$316,551 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 41 | $171,578 |
| VemlidyTenofovir Alafenamide | 43 | $78,509 |
| LinzessLinaclotide | 36 | $29,185 |
| Mesalamine | 41 | $28,052 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 90 | $15,774 |
| Ursodiol | 86 | $10,752 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 148 | $8,467 |
| Mesalamine ErMesalamine | 18 | $6,819 |
| Balsalazide Disodium | 17 | $4,346 |
| Tacrolimus | 22 | $2,848 |
| Famotidine | 184 | $2,714 |
| Mycophenolate Mofetil | 24 | $2,460 |
| Budesonide EcBudesonide | 12 | $2,439 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 12 | $1,966 |
| Omeprazole | 148 | $1,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $246 | $171,57841 claims |
| GileadVemlidy | $136,436 | $78,50943 claims |
| AbbVieLinzess | $43,716 | $29,18536 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $115 | $15,77490 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Hartford
- Colin SwalesHartford$285K
- Michael EinsteinHartford$139K
- Lisa RossiHartford$40K
- David ChaletskyHartford$19K
- Paul FeuerstadtHamden$1M
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Joseph CappaGlastonbury$200K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.